[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648335":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":24,"centralContacts":29,"locations":40,"responsibleParty":59,"collaborators":61,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":19,"enrollmentInfo":76,"targetDuration":19,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":94,"whyStopped":19,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Mild Hemophilia Assessment","Patients with mild hemophilia will undergo an evaluation of joint health and functional status. Assessments will include joint ultrasound (HEAD-US) of six joints (ankles, knees, and elbows), blood sampling to determine FVIII or FIX activity, completion of functional, quality-of-life, and physical activity questionnaires, and clinical evaluation using the HemoFAST score. No therapeutic intervention or follow-up is planned as part of the study.",[12,13],"Other: Joint Ultrasound (HEAD-US)","Other: Blood Sample for Coagulation Factor Measurement",[15,20],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Joint Ultrasound (HEAD-US)","Ultrasound evaluation of six joints (both ankles, knees, and elbows) by a designated expert using the HEAD-US scoring system to assess joint health and detect early arthropathy.",[9],null,{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":19},"Blood Sample for Coagulation Factor Measurement","Blood sample collected according to local laboratory procedures to measure coagulation factor activity (FVIII for hemophilia A, FIX for hemophilia B).",[9],[25],{"name":26,"affiliation":27,"role":28},"Laurent FRENZEL","Hôpital Necker Enfants Malades AP-HP","PRINCIPAL_INVESTIGATOR",[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Laurent FRENZEL, MD PhD","CONTACT","01 44 49 52 92","+33","laurent.frenzel@aphp.fr",{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},"Sarah BOUCHARD, Project Manager","01 42 19 28 79","sarah.bouchard@aphp.fr",[41],{"facility":42,"status":19,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hôpital Necker Enfants malades","Paris","Île-de-France Region","75015","France","FR",{"type":49,"coordinates":50},"Point",[51,52],2.3488,48.85341,{"lat":52,"lon":51},[55,56,57],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},{"name":37,"role":32,"phone":38,"phoneExt":34,"email":39},{"name":58,"role":28,"phone":19,"phoneExt":19,"email":19},"Laurent FRENZEL, MD phD",{"type":60,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[62,64],{"name":63,"class":6},"URC-CIC Paris Descartes Necker Cochin",{"name":65,"class":66},"Swedish Orphan Biovitrum","INDUSTRY","100648335","ultrasound-assessment-of-joint-health-in-patients-with-mild-hemophilia-factor-levels-5-40-100648335",false,"NCT07719647","Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)","echoSAHM","Inclusion Criteria:\n\n* Adult (≥18 years old) with congenital mild hemophilia, defined as historical coagulation factor level \\>5% and \\\u003C40% (FVIII or FIX).\n* Affiliated with a social security system.\n* Provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patient on prophylactic treatment, defined as at least one of the following:\n\n  o. ≥5 factor concentrate injections per month for a period of more than 6 months o. Treatment with emicizumab o. Last factor concentrate injection within the past 28 days\n* Patient with acquired hemophilia.\n* Patient with uncontrolled chronic rheumatologic disease, such as rheumatoid arthritis, inflammatory spondyloarthropathies, or microcrystalline arthritis.\n* Known pregnancy or breastfeeding.\n* Patient deprived of liberty or under legal guardianship or conservatorship.","ALL","18 Years",{"count":77,"type":78},150,"ESTIMATED","INTERVENTIONAL",[81],"NA","Currently, few recommendations exist for patients with mild hemophilia, who represent approximately 60% of the hemophilia population. This study aims to provide objective data on joint health in these patients, which are currently limited compared to those with moderate or severe hemophilia.\n\nThe use of joint ultrasound in mild hemophilia could allow early, asymptomatic detection of joint damage, support tailored management including patient education, and ultimately improve quality of life.\n\nThe study will also explore the correlation between coagulation factor levels (FVIII or FIX) and other indicators of joint health in France.",[84],"Mild Hemophilia",[84,86,87,88,89,90,91,92,93],"Hemophilia A","Hemophilia B","Joint Health","Arthropathy","Ultrasound","HEAD-US","Coagulation Factor","Quality of life","NOT_YET_RECRUITING","2026-08-13",{"date":97,"type":98},"2026-08-17","ACTUAL",{"date":100,"type":78},"2027-02",{"date":102,"type":78},"2028-02",{"name":5,"class":6},1]